Bank Hapoalim

POLI.TA

Earnings and TP upgrade

- Hapoalim's Q3 earings were significantly better than we expected, but the two main drivers, margins and provisioning, should normalise in Q4, in our view.
- Segmental reporting shows that customer business contributed little to earnings growth in 9M05. The increase in operating earnings was driven mainly by treasury activities.
- We have raised our 2005 and 2006 earnings forecasts by 4% and 6% respectively. This is due to strong Q3 results, as well as improvements in asset quality.
- Based on changes in cost of equity and ROE, we are increasing our 12-month target price to ILS 18.6 from ILS 16.3. We keep a Neutral rating on the stock.

Bank Hapoalim is Israel's largest bank with a third of the Israeli market, offering personal, corporate and institutional banking services.

Rating	NEUTRAL*
Price (22 Nov 05)	18.11 (NIS)
Target price (12 months)	18.60 (NIS)
Market cap. (NIS m)	22,782.58
Enterprise value (NIS m)	22,782.58
Region/country	Europe/Israel
Sector	Regional Banks
Analyst's Coverage Universe	Emerging Markets
Weighting (vs. broad market)	0
Date	23 November 2005

^{*} Stock ratings are relative to the coverage universe in each analyst's or each team's respective sector.



The price relative chart measures performance against the Israel TA100 index On 22/11/05 the Israel TA100 index closed at 762.67 On 22/11/05 the spot exchange rate was NIS5.59/Eu 1. - Eu 0.85/US\$1

Performance over		1mth	3mths	12mths
Absolute (%)		3.2	10.8	38.0
Relative (%)		1.8	5.4	6.1
Year	12/03A	12/04A	12/05E	12/06E
PCC Operating profit	4,421.0	4,908.0	5,166.3	5,354.7
Net income (NIS m)	1,357.0	2,107.0	2,878.8	2,441.0
EPS stated (NIS)	1.09	1.69	2.31	1.96
CSFB adj. EPS (NIS)	0.97	1.46	1.83	1.96
CSFB adj. BVPS (NIS)	11.42	12.15	13.12	13.95
CSFB adj. ROE (%)	8.9	12.4	14.5	14.4
P/E (adj., x)	18.59	12.37	9.89	9.26
P/E rel (%)	58.95	54.25	53.03	65.70
P/BVPS (adj., x)	1.59	1.49	1.38	1.30

Dividend 2005E (NIS)	Free float (%)
1.33	55.1
Dividend yield (%)	Number of shares (m)
7.3	1,258.01
CSFB adj. equity (12/05E, NIS)	Current cost of equity (12/05E,
16,384.7	11.0
Net int margin (12/05E, %)	Tier 1 ratio (12/05E, %)
2.8	11.0
Cost/income (12/05E, %)	52-wk range (NIS)
56.9	18 - 13

Source: FTI, Company data, Datastream, CSFB (EUROPE) LTD. Estimates

research team

Andrzej Nowaczek, CFA

Research Analyst 44 20 7888 2852 andrzej.nowaczek@csfb.co Bank Hapoalim

Investment Summary

Results recap

Hapoalim's Q3 earnings beat our forecast by 25% owing to both better than expected net interest income and lower provisioning charges. The former was due mainly to treasury's asset liability management, while the latter was impacted mainly by recoveries. According to management, the near-term margin outlook is stable, while provisioning should increase.

Most other items were in line with our expectations. Non-interest income was up strongly - fees from capital markets were up 25% to ILS 402m, driven mainly by a 62% increase in equity market trading volumes, while credit card fees also contributed strongly, up 16%. Personnel costs were slightly disappointing, up 13% on bonus accruals, but other operating costs increased only 12% compared with an 18% increase in Q2.

At 0.4% qoq, loan growth remained weak despite strong macro fundamentals. As in previous quarters, corporates preferred to issue debt. Hapoalim reported a 31% quarterly increase in its exposure to corporate bonds, a total of 1.8% growth in corporate business. Corporate deposits were up 9% in the quarter and 50% year-to-date. This suggests to us that demand for credit will remain weak in the near term.

Segmental performance showed a significant improvement in corporate profitability, we believe mainly due to decline in provisioning charges. This drove a 9% increase in profits from client business, with retail profits up 14%. However, in the nine-month period, corporate profits were still down 10% compared with 2004, and overall client business profits were up a mere 3.5%.

We estimate that of the 40% earnings growth in 9M05, 64% came from disposals and 30% was generated from non-client business. The later is consistent with management's strategy to increase risk taking in the treasury department.

Change in forecasts and price target

In the conference call, management said that there was a high probability that its 2005 ROE goal of 14% will be exceeded. Following Q3 results, we believe this is certainly going to be the case. We have therefore raised our 2005 adjusted earnings forecast by 4% to ILS 2,286m, which translates into an ROE of 14.5%.

This implies Q4 net profit of ILS 591m, which we believe is consistent with management's view that Q3 provisioning was below what should be expected as average and the fact that a large chunk of net interest margin improvement may not be recurring. We have also increased our 2006 earnings forecast by 6% on the back of both revenue increase and reduction of credit costs. Our 2006 forecasts imply 7% earnings growth.

We maintain a Neutral rating on the stock but we have raised our share price from ILS 16.3 to ILS 18.6. This is driven by a combination of a lower risk free rate and higher ROE forecast, as well as rolling forward by six months. We continue to believe that for a substantial re-rating, a change in client business mix is needed rather than more risk taking in treasury operations.

Figure 1: Price target assumptions

In %, unless otherwise stated

	2002-2006E	2007E+
Risk-free rate	6.0	6.0
Risk premium	5.0	5.0
Beta (x)	1.00	1.00
Cost of equity	11.0	11.0
Growth in assets	0.7	3.5
ROA	0.7	0.8
Dividend payout	52	77
Dividend growth	15.8	3.6
Average ROE	10.8	12.9
Average E/A	5.8	5.9

Source: Company data, CSFB estimates

Figure 2: Summary income statement

NIS in millions

	2003	2004	2005E	2006E
Interest income	9,996	13,549	14,056	14,035
Interest expense	-3,281	-6,478	-6,585	-6,262
Net interest income	6,715	7,071	7,471	7,773
Fee and commission income	2,929	3,199	3,439	3,611
Trading income	3	109	87	89
Other non-interest income	733	907	998	1,053
Total non-interest income	3,665	4,215	4,524	4,752
Total operating income	10,380	11,286	11,995	12,525
Staff costs	-3,526	-3,742	-4,023	-4,224
Other operating costs	-2,433	-2,636	-2,806	-2,946
Total operating costs	-5,959	-6,378	-6,829	-7,170
Operating profit before provisions	4,421	4,908	5,166	5,355
Provision expense	-2,359	-1,768	-1,272	-1,279
Extraordinaries	141	279	593	0
Pre-tax profit	2,203	3,419	4,487	4,076
Taxes	-861	-1,361	-1,639	-1,655
Net profit	1,342	2,058	2,848	2,421
Income from affiliates	63	101	126	120
Minorities	-48	-52	-95	-100
Attributable net profit	1,357	2,107	2,879	2,441

Source: Company data, CSFB estimates

Bank Hapoalim 23 November 2005

Companies Mentioned (Price as of 22 Nov 05)

Bank Hapoalim (POLI.TA, NIS18.11, NEUTRAL, TP NIS18.60)


Disclosure Appendix

Important Global Disclosures

The analysts identified in this report each certify, with respect to the companies or securities that the individual analyzes, that (1) the views expressed in this report accurately reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.

See the Companies Mentioned section for full company names.

3-Year Price, Target Price and Rating Change History Chart for POLI.TA



POLI.TA Closing Price Target Price Initiation/ Date Price (ILS) Price (ILS) Rating Assumption 28-Nov-02 7.34 9 20-Mar-03 6.69 7.6 **NEUTRAL** 30-May-03 9.44 10.4 07-Jun-04 12.05 11.7 13-Sep-04 Χ 14.77 16.3 23-Mar-05

The analyst(s) responsible for preparing this research report received compensation that is based upon various factors including CSFB's total revenues, a portion of which are generated by CSFB's investment banking activities.

Analysts' stock ratings are defined as follows***:

Outperform: The stock's total return is expected to exceed the industry average* by at least 10-15% (or more, depending on perceived risk) over the next 12 months.

Neutral: The stock's total return is expected to be in line with the industry average* (range of $\pm 10\%$) over the next 12 months.

Underperform:** The stock's total return is expected to underperform the industry average* by 10-15% or more over the next 12 months.

*The industry average refers to the average total return of the analyst's industry coverage universe (except with respect to Asia/Pacific, Latin America and Emerging Markets, where stock ratings are relative to the relevant country index, and CSFB Small and Mid-Cap Advisor stocks, where stock ratings are relative to the regional CSFB Small and Mid-Cap Advisor investment universe.

Bank Hapoalim 23 November 2005

**In an effort to achieve a more balanced distribution of stock ratings, the Firm has requested that analysts maintain at least 15% of their rated coverage universe as Underperform. This guideline is subject to change depending on several factors, including general market conditions.

***For Australian and New Zealand stocks a 7.5% threshold replaces the 10% level in all three rating definitions.

Restricted: In certain circumstances, CSFB policy and/or applicable law and regulations preclude certain types of communications, including an investment recommendation, during the course of CSFB's engagement in an investment banking transaction and in certain other circumstances.

Volatility Indicator [V]: A stock is defined as volatile if the stock price has moved up or down by 20% or more in a month in at least 8 of the past 24 months or the analyst expects significant volatility going forward. All CSFB Small and Mid-Cap Advisor stocks are automatically rated volatile. All IPO stocks are automatically rated volatile within the first 12 months of trading.

Analysts' coverage universe weightings* are distinct from analysts' stock ratings and are based on the expected performance of an analyst's coverage universe** versus the relevant broad market benchmark***:

Overweight: Industry expected to outperform the relevant broad market benchmark over the next 12 months.

Market Weight: Industry expected to perform in-line with the relevant broad market benchmark over the next 12 months.

Underweight: Industry expected to underperform the relevant broad market benchmark over the next 12 months

*CSFB Small and Mid-Cap Advisor stocks do not have coverage universe weightings.

**An analyst's coverage universe consists of all companies covered by the analyst within the relevant sector.

***The broad market benchmark is based on the expected return of the local market index (e.g., the S&P 500 in the U.S.) over the next 12 months.

CSFB's distribution of stock ratings (and banking clients) is: Global Ratings Distribution

Outperform/Buy*	40%	(65% banking clients)
Neutral/Hold*	44%	(63% banking clients)
Underperform/Sell*	14%	(55% banking clients)
Restricted	3%	

*For purposes of the NYSE and NASD ratings distribution disclosure requirements, our stock ratings of Outperform, Neutral, and Underperform most closely correspond to Buy, Hold, and Sell, respectively; however, the meanings are not the same, as our stock ratings are determined on a relative basis. (Please refer to definitions above.) An investor's decision to buy or sell a security should be based on investment objectives, current holdings, and other individual factors.

CSFB's policy is to update research reports as it deems appropriate, based on developments with the subject company, the sector or the market that may have a material impact on the research views or opinions stated herein.

CSFB's policy is only to publish investment research that is impartial, independent, clear, fair and not misleading. For more detail please refer to CSFB's Policies for Managing Conflicts of Interest in connection with Investment Research: http://www.csfb.com/research-and-analytics/disclaimer/managing_conflicts_disclaimer.html

CSFB does not provide any tax advice. Any statement herein regarding any US federal tax is not intended or written to be used, and cannot be used, by any taxpayer for the purposes of avoiding any penalties.

See the Companies Mentioned section for full company names.

Price Target: (12 months) for (POLI.TA) **Method:** Price to book versus ROE

Risks: Macroeconomic

See the Companies Mentioned section for full company names.

The subject company (POLI.TA) currently is, or was during the 12-month period preceding the date of distribution of this report, a client of CSFB.

CSFB provided investment banking services to the subject company (POLI.TA) within the past 12 months. CSFB provided non-investment banking services, which may include Sales and Trading services, to the subject company (POLI.TA) within the past 12 months.

CSFB has received investment banking related compensation from the subject company (POLI.TA) within the past 12 months.

Bank Hapoalim

CSFB expects to receive or intends to seek investment banking related compensation from the subject company (POLI.TA) within the next 3 months.

CSFB has received compensation for products and services other than investment banking services from the subject company (POLI.TA) within the past 12 months.

Important Regional Disclosures

The analyst(s) involved in the preparation of this report have not visited the material operations of the subject company (POLI.TA) within the past 12 months.

Restrictions on certain Canadian securities are indicated by the following abbreviations: NVS--Non-Voting shares; RVS--Restricted Voting Shares; SVS--Subordinate Voting Shares.

Individuals receiving this report from a Canadian investment dealer that is not affiliated with CSFB should be advised that this report may not contain regulatory disclosures the non-affiliated Canadian investment dealer would be required to make if this were its own report.

For Credit Suisse First Boston Canada Inc.'s policies and procedures regarding the dissemination of equity research, please visit http://www.csfb.com/legal_terms/canada_research_policy.shtml.

As of the date of this report, CSFB acts as a market maker or liquidity provider in the equities securities that are the subject of this report.

For disclosure information on other companies mentioned in this report, please visit the website at www.csfb.com/researchdisclosures or call +1 (877) 291-2683.

Disclaimers continue on next page.



Disclaimers

Credit Suisse First Boston is the trade name for the investment banking business of Credit Suisse, a Swiss bank, and references in this report to Credit Suisse First Boston or CSFB herein include all of the subsidiaries and affiliates of Credit Suisse operating under the Credit Suisse First Boston division of Credit Suisse Group ("CSG"). For more information on our structure, please follow the below link: http://www.creditsuisse.com/en/who_we_are/ourstructure.html.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Credit Suisse or its subsidiaries or its affiliates ("CS") to any registration or licensing requirement within such jurisdiction. All material presented in this report, unless specifically indicated otherwise, is under copyright to CS. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of CS. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of CSG or its affiliates.

The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. CS may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. CS will not treat recipients as its customers by virtue of their receiving the report. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal recommendation to you. CS does not offer advice on the tax consequences of investment and you are advised to contact an independent tax adviser. Please note in particular that the bases and levels of taxation may change. CS believes the information and opinions in the Disclosure Appendix of this report are accurate and complete. Information and opinions presented in the other sections of the report were obtained or derived from sources CS believes are reliable, but CS makes no representations as to their accuracy or completeness. Additional information is available upon request. CS accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to CS. This report is not to be relied upon in substitution for the exercise of independent judgment. CS may have issued, and may in the future issue, a trading call regarding this security. Trading calls are short term trading opportunities based on market events and catalysts, while stock ratings reflect investment recommendations based on expected total return over a 12-month period relative to the relevant coverage universe. Because trading calls and stock ratings reflect different assumptions and analytical methods, trading calls may differ directionally from the stock rating. In addition, CS may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and CS is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report. CS is involved in many businesses that relate to companies mentioned in this report. These businesses include specialized trading, risk arbitrage, market making, and other proprietary trading.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgement at its original date of publication by CS and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Investors in securities such as ADR's, the values of which are influenced by currency volatility, effectively assume this risk.

Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct their own investigation and analysis of the product and consult with their own professional advisers as to the risks involved in making such a purchase.

Some investments discussed in this report have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when that investment is realised. Those losses may equal your original investment. Indeed, in the case of some investments the potential losses may exceed the amount of initial investment, in such circumstances you may be required to pay more money to support those losses. Income yields from investments may fluctuate and, in consequence, initial capital paid to make the investment may be used as part of that income yield. Some investments may not be readily realisable and it may be difficult to sell or realise those investments, similarly it may prove difficult for you to obtain reliable information about the value, or risks, to which such an investment is exposed. This report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of CSG, CS has not reviewed the linked site and takes no responsibility for the content contained therein. Such address or hyperlink (including addresses or hyperlinks to CSG's own website material) is provided solely for your convenience and information and the content of the linked site does not in any way form part of this document. Accessing such website or following such link through this report or CSG's website shall be at your own risk.

website or following such link through this report or CSG's website shall be at your own risk.

This report is issued and distributed in Europe (except Switzerland) by Credit Suisse First Boston (Europe) Limited, One Cabot Square, London E14 4QJ, England, which is regulated in the United Kingdom by The Financial Services Authority ("FSA"). This report is being distributed in the United States by Credit Suisse First Boston LLC; in Switzerland by Credit Suisse; in Canada by Credit Suisse First Boston Canada Inc.; in Brazil by Banco de Investimentos Credit Suisse First Boston S.A.; in Japan by Credit Suisse First Boston Securities (Japan) Limited; elsewhere in Asia/Pacific by whichever of the following is the appropriately authorised entity in the relevant jurisdiction: Credit Suisse First Boston (Hong Kong) Limited, Credit Suisse First Boston Australia Equities Limited, Credit Suisse First Boston (Thailand) Limited, CSFB Research (Malaysia) Sdn Bhd, Credit Suisse Singapore Branch and elsewhere in the world by the relevant authorised affiliate of the above. Research on Taiwanese securities produced by Credit Suisse Taipei Branch has been prepared by a registered Senior Business Person.

In jurisdictions where CS is not already registered or licensed to trade in securities, transactions will only be effected in accordance with applicable securities legislation, which will vary from jurisdiction to jurisdiction and may require that the trade be made in accordance with applicable exemptions from registration or licensing requirements. Non-U.S. customers wishing to effect a transaction should contact a CS entity in their local jurisdiction unless governing law permits otherwise. U.S. customers wishing to effect a transaction should do so only by contacting a representative at Credit Suisse First Boston LLC in the U.S.

Please note that this report was originally prepared and issued by CS for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of CS should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. This research may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA or in respect of which the protections of the FSA for private customers and/or the UK compensation scheme may not be available, and further details as to where this may be the case are available upon request in respect of this report.

Any Nielsen Media Research material contained in this report represents Nielsen Media Research's estimates and does not represent facts. NMR has neither reviewed nor approved this report and/or any of the statements made herein.

Copyright 2005 CREDIT SUISSE and/or its affiliates. All rights reserved.

ASIA/PACIFIC: +852 2101-6000 EUROPE: +44 (20) 7888-8888 UNITED STATES OF AMERICA: +1 (212) 325-2000